Call +44 (0)1904 798634 or +44 (0)7550 079918

Leading provider of life science market reports and research services

EpiCast Report: Non-Hodgkin's Lymphoma - Epidemiology Forecast to 2024

Be the first to review this product

EpiCast Report: Non-Hodgkin's Lymphoma - Epidemiology Forecast to 2024


Non-Hodgkin's Lymphoma (NHL) refers to a group of cancers that develop in the lymphatic system. In NHL, the body's...
You can choose to pay by purchase order during checkout

Availability: In stock


* Required Fields

You can choose to pay by purchase order during checkout

Digital downloads direct to your inbox within 24 hours.

First class customer service from our team of experts.

Pay by credit card or request an invoice

Product Description


EpiCast Report: Non-Hodgkin's Lymphoma - Epidemiology Forecast to 2024


Non-Hodgkin's Lymphoma (NHL) refers to a group of cancers that develop in the lymphatic system. In NHL, the body's immune system is affected by the uncontrollable growth of malignant white blood cells, resulting in the body's inability to fight infections and other diseases. NHL is characterized into three types - B-cell, T-cell, and natural killer lymphocyte lymphomas. This epidemiological analysis focuses specifically on four subtypes of B-cell NHL: follicular lymphoma, marginal zone lymphoma, diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma. NHL is more common in men than in women, in white men and women compared with black men and women, and the incidence exponentially increases with age.

GlobalData epidemiologists forecast an increase in the incident cases of the four B-cell NHL in the 7MM, from 104,854 incident cases in 2014 to 129,179 incident cases in 2024, with an annual growth rate (AGR) of 2.32%. Throughout the forecast period, the US will have the highest number of incident cases of B-cell NHL, as well as 36% growth during the forecast period, ending with 57,724 incident cases in 2024. Additionally, each of the 7MM will see an increase in incident cases over the 10-year forecast period.

For this analysis, GlobalData epidemiologists utilized peer-reviewed journals and country-specific disease databases to construct the 10-year epidemiological forecast for the incident cases of follicular lymphoma, marginal zone lymphoma, DLBCL, and mantle cell lymphoma in the 7MM. A major strength of GlobalData's epidemiological analysis is the exclusive use of country-specific sources, allowing for a meaningful comparison of the epidemiological characteristics of B-cell NHL in the 7MM. In addition, this forecast provides detailed segmentation of the B-cell NHL for each country by age, sex, and B-cell NHL subtype, thereby providing a comprehensive view of B-cell NHL in the seven markets. Furthermore, GlobalData epidemiologists constructed and analyzed each B-cell NHL subtype individually, which facilitated an in-depth understanding of B-cell NHL in the 7MM.


- The Non-Hodgkin's Lymphoma (NHL) EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for NHL in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast of the incident cases of NHL segmented by sex, age (in five-year increments beginning at 30 years and ending at =85 years), and subtypes in these markets.
- The NHL epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 10MM.

Reasons to buy

The NHL EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global NHL market.
- Quantify patient populations in the global NHL market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for NHL therapeutics in each of the markets covered.

Additional Information

Additional Information

Publisher name GlobalData.
Format PDF
Page count 67
Publication date 1 Jan 2016
Table of contents 1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 Catalyst 7
2.2 Related Reports 8
2.3 Upcoming Reports 8
3 Epidemiology 9
3.1 Disease Background 9
3.2 Risk Factors and Comorbidities 9
3.3 Global Trends 12
3.3.1 US 12
3.3.2 5EU 13
3.3.3 Japan 16
3.4 Forecast Methodology 16
3.4.1 Sources Used 19
3.4.2 Sources Not Used 22
3.4.3 Forecast Assumptions and Methods 23
3.5 Epidemiological Forecast for B-Cell NHL (2014-2024) 27
3.5.1 Follicular Lymphoma 27
3.5.2 Marginal Zone Lymphoma 35
3.5.3 DLBCL 42
3.5.4 Mantle Cell Lymphoma 49
3.6 Discussion 56
3.6.1 Epidemiological Forecast Insight 56
3.6.2 Limitations of the Analysis 56
3.6.3 Strengths of the Analysis 57
4 Appendix 58
4.1 Bibliography 58
4.2 About the Authors 62
4.2.1 Epidemiologists 62
4.2.2 Reviewers 63
4.2.3 Global Director of Therapy Analysis and Epidemiology 64
4.2.4 Global Head of Healthcare 64
4.3 About GlobalData 65
4.4 About EpiCast 65
4.5 Disclaimer 66


Write Your Own Review

Only registered users can write reviews. Please, log in or register

Product Tags

Product Tags

Use spaces to separate tags. Use single quotes (') for phrases.